WJPMR, 2026, 12(6), 103-112

Review Article

Impact Factor: 7.533

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

PHARMACOVIGILANCE AND HERBAL MEDICINE SAFETY: A COMPRIHENSIVE REVIEW

Neelam Thakur*, Harsh Thakur, Kavita Pathania, Pooja Sharma

Dreamz College of Pharmacy, Khilra Sundernagar, Himachal Pradesh, India.

***Corresponding Author: Neelam Thakur**

Dreamz College of Pharmacy, Khilra Sundernagar, Himachal Pradesh, India.

DOI: https://doi.org/10.5281/zenodo.20454770

How to cite this Article: Neelam Thakur*, Harsh Thakur, Kavita Pathania, Pooja Sharma (2026). Pharmacovigilance And Herbal Medicine Safety: A Comprihensive Review. World Journal of Pharmaceutical and Medical Research, 12(6), 103–112.

Article Received on 29/04/2026 **Article Revised on 19/05/2026** **Article Published on 01/06/2026**

ABSTRACT

Background: Pharmacovigilance (PV) used to deal mostly with synthetic drugs, yet now it also covers herbal medicines because their use keeps growing worldwide. A lot of people still think "natural automatically equals safe," and that idea is genuinely risky. Herbal treatments are not fully safe. They may contain complex chemicals that can cause serious adverse drug reactions (ADRs), even severe organ toxicity. **Objective:** This review looks at the urgent need for dedicated herbal pharmacovigilance, using *Papaver somniferum* (the opium poppy) as the main clinical example to show the real pharmacological strength, narrow therapeutic range, and serious herb-drug interactions (HDIs) found in plant-based medicines. **Scope of Review:** The study looks at global systems used to monitor herbal safety, with close attention to the WHO Programme for International Drug Monitoring, VigiBase, and the Indian Pharmacopoeia. It also examines why standard causality tools like the WHO-UMC scale often do not fit multi-compound botanicals very well. Then it compares uneven regulations, especially the European Union's THMPD and the United States' DSHEA. **Key Findings:** The assessment points to chronic underreporting, natural chemical variability, and some pretty serious regulatory loopholes as the main obstacles to botanical safety. Even so, the field is moving into "Vigilance 2.0." This shift leaves passive reporting behind and leans on technology-driven surveillance, using molecular fingerprinting, AI-based signal detection, social listening, and pharmacogenomics to catch hidden toxicities and prevent dangerous synergistic interactions. **In conclusion:** bringing herbal medicine into modern healthcare needs strict and shared scientific oversight. Current problems won't be solved without better global regulation, the use of Real-World Evidence (RWE), and more honest communication between clinicians and patients. In the end, stronger pharmacovigilance is what makes traditional botanicals safer without putting public health at risk.

KEYWORDS: Pharmacovigilance, Herbal Pharmacovigilance, Phytovigilance, Herbal Medicines, Botanical Medicines, Drug Safety, Adverse Drug Reactions (ADRs), Herb-Drug Interactions (HDIs), *Papaver somniferum*.

1. INTRODUCTION

1.1 Defining Pharmacovigilance in Real-World Use

What happens when a medicine leaves the controlled space of a clinical trial and enters daily life? That is where pharmacovigilance begins. At its core, it means the "systematic review of product safety once released on the market" for public use. Instead of leaning only on early laboratory findings, this field follows a product's safety profile while ordinary people are actually using it. The aim is direct enough: find harmful side effects, adverse events, or drug interactions that early trials often miss. These monitoring systems were first built for synthetic drugs, yet regulatory guidance has gradually widened to include vaccines, blood products, medical devices, and botanical remedies too.

1.2 The "Natural Equals Safe" Misconception

Herbal and plant-based treatments have surged in popularity around the world, and reports of toxicity and health problems have risen with them. That is not surprising when you think about one stubborn consumer belief: natural automatically means safe. It does not. In fact, this idea is misleading and, frankly, risky. A large share of commercial herbal supplements skips the strict toxicological testing required for standard synthetic medicines. For that reason, ongoing pharmacovigilance is not just useful. It is necessary.[1]

1.3 Categorizing Adverse Reactions

When patients do have negative effects from herbal remedies, the problems usually fit into one of these groups:

- **Adverse Drug Reactions (ADRs):** These are expected biological effects that happen because of how the drug naturally works and interacts in the body (pharmacodynamics).
- **Drug-Use Related Events:** These side effects come from taking doses that are too high or using the botanical product for much longer than it's meant to be used.
- **Immune / Individual Events:** Reactions caused by a person's own biological sensitivity, like sudden allergies or hypersensitivity, and these are watched closely in safety monitoring.
- **Organ Adverse Events:** Medium- or long-term physical harm that affects how vital organs work, especially the heart, liver, kidneys, or the central nervous system.
- **Genetic / Developmental:** Serious toxicity that changes genetic makeup or physical development. This usually shows up in longer toxicology studies or during extended clinical follow-up.
- **Abuse / Dependency:** Problems linked directly to a medicine's addictive potential, or the body's risk of becoming dependent on it over time.

2. CONCEPT OF PHARMACOVIGILANCE

2.1 The Limits of Controlled Clinical Trials

Before a new medicine appears on pharmacy shelves, it normally passes through clinical trials. These studies are tightly controlled, and that makes sense because researchers have to show whether a drug really works and whether it's broadly safe. The problem is, trials exist in something like a bubble. They often include a fairly small group of carefully chosen participants, not the full range of people who will later use the medicine. People with several illnesses, pregnant women, or patients already taking a complicated set of other drugs are often left out, mainly to keep the data clean. That makes the results easier to read, yet it also strips away real-life complexity. On top of that, many trials run only for a few months, sometimes a couple of years. In practice, everyday use is far messier, and that gap matters a lot.

2.2 The Reality of Everyday Life Monitoring

Once a product gets approved and reaches the public, everything changes. In clinical trials, there may be only a few thousand participants, and they are watched very closely. In real life, though, millions of people start using it, and that is a completely different situation. These people do not live under controlled conditions. They come from different genetic backgrounds, eat different foods, and follow very different habits. Some are already sick. Some are getting older. Many also take the product together with prescription drugs or even common supplements from the pharmacy, and that can change outcomes in ways trials never fully catch.

That is why pharmacovigilance could not stay focused only on pre-market testing. It had to move toward constant post-market surveillance. A rare but serious adverse effect may appear in only 1 out of 10,000 users, and a trial with 3,000 patients will probably miss it. In other cases, organ damage or dependency may take years to show up. Everyday monitoring matters because it catches risks that labs simply cannot foresee.

2.3 Why This Shift Matters for Herbal Medicine

This move toward real-world monitoring matters even more with herbal medicines like *Papaver somniferum*. Synthetic drugs usually have one purified active ingredient. Botanical products do not work that way. They are messy mixtures, often packed with dozens, sometimes hundreds, of chemical compounds, and that makes them much harder to judge with confidence. It is honestly very difficult to predict how those compounds will act once they mix with prescription medicines, daily stress, or even a specific diet. A short clinical trial cannot fully catch that.

Real-world pharmacovigilance, then, is not just helpful, it is necessary. It shows that safety testing does not stop when a product reaches the market. In many cases, that is exactly when the serious and most useful tracking starts.

3. THE NEED FOR HERBAL PHARMACOVIGILANCE

3.1 Breaking Down the "Natural is Safe" Myth

In many cultures, there is this dumb idea that if a remedy comes from the earth, it must be mild and basically harmless. That belief, the "natural equals safe" myth, is probably one of the biggest problems in herbal medicine right now. The truth is less comforting. Nature is an excellent chemist, and it also makes some of the strongest toxins on Earth.[2] *Papaver somniferum* (the opium poppy) shows this clearly: it is completely natural, yet it contains potent alkaloids that can cause serious respiratory depression or even fatal overdose. When consumers, and honestly even some healthcare providers, act as if botanical products have no real risk, the result is dangerous. People start taking large doses casually, without much caution, and that false sense of safety can do real harm.[3]

3.2 The Complexity of the Plant Matrix

To see why herbal pharmacovigilance is genuinely necessary, it helps to look at how these medicines are actually made up. A typical synthetic drug often has one highly purified active molecule, and that gives scientists a fairly clear idea of how it should behave. Herbal medicine is not like that at all. One plant extract can contain dozens, sometimes even hundreds, of chemical compounds working at the same time.[4] When a person takes an herbal remedy, they are not taking one neat substance. They are taking something closer to a mixed drug cocktail, and that matters. The plant's growing conditions, including soil quality, climate, and where it was cultivated, can shift the strength of those compounds

quite a lot between batches. That inconsistency is frustrating, honestly. A small short-term trial cannot reliably show how such a messy plant matrix will affect millions of different users. Ongoing, active monitoring is really the only practical way to catch harmful reactions.

3.3 The Hidden Danger of Herb-Drug Interactions

Another big reason we need dedicated herbal pharmacovigilance is drug interactions. Most patients do not take only one product. Someone may be on a prescribed blood thinner, use a daily multivitamin, and also take an herbal supplement at the same time. That mix sounds harmless, though it really is not. When botanicals interact with synthetic drugs in the body, the outcome can turn dangerous fast.[5] Some herbs change the way the liver handles other medicines. They may speed metabolism up, which leaves the prescription drug less effective, or slow it down, which can lead to a toxic buildup in the bloodstream. What makes this worse is simple and frustrating: many patients do not see herbs as "real medicine," so they never mention them to doctors, and these risky interactions stay hidden.[6]

3.4 The Regulatory Blind Spot

Finally, there is a serious regulatory gap, and it makes pharmacovigilance not just useful, but necessary. For a synthetic drug to enter the market, it usually goes through years of demanding safety trials. In many countries, though, herbal supplements are handled more like food than actual medicine. That means they often skip strict pre-market testing almost completely.[7] Under this kind of system, an herbal product is removed from shelves only after it has already shown itself to be dangerous to the public. That approach is plainly backwards. The first regulatory barrier is left far too open, and because of that, post-market surveillance, pharmacovigilance, ends up being the only real safety net for consumers. It is a critical tool for the medical community to detect toxic effects, adulteration, and hidden risks before they grow into wider public health problems.[8]

4. THE GLOBAL PHARMACOVIGILANCE SYSTEM AND THE WHO'S ROLE

4.1 The Need for a Global Safety Net

When it comes to keep track adverse drug reactions, working alone is not an efficient option. A rare side effect may show up only once in a million doses, which is exactly why one country cannot rely only on its own records. It could take years, even decades, before a harmful pattern becomes visible. With international data sharing, though, health authorities can catch these “safety signals” much earlier, and that difference matters. This is especially important for herbal medicines such as *Papaver somniferum*. These botanicals are usually grown in fairly specific regions, yet they are shipped, sold, and consumed across the world. That creates a clear problem: the risks do not stay local, so the safety system should not stay local either.[9]

4.2 The WHO Programme for International Drug Monitoring

To deal with this geographic gap, the World Health Organization (WHO) took action. After the thalidomide disaster in the 1960s, which still stands as one of the clearest warnings in drug safety history, WHO created the Programme for International Drug Monitoring (PIDM). The network is now extensive, with more than 170 member countries involved. Rather than leaving each country to handle drug toxicity on its own, the programme gathers local adverse event reports into one central system.[10] The Uppsala Monitoring Centre (UMC) in Sweden runs the technical and scientific work behind this global effort.

At the center of the UMC’s work sits VigiBase, which is basically the biggest pharmacovigilance database in the world. When a doctor in India, a pharmacist in Germany, or even a clinic in Brazil reports a serious reaction to an opiate or an herbal extract, that report gets standardized and sent directly into VigiBase. After that, advanced statistical algorithms, watched closely by clinical experts, keep scanning the data for disproportionate reporting. If one batch of an herbal product starts showing strange toxicity in three continents at the same time, VigiBase is the system that spots the pattern and raises the global alarm.[11]

For years, the global monitoring system focused almost entirely on synthetic pharmaceuticals. Herbal medicines were mostly pushed aside, which honestly was a major gap. As international trade in botanicals expanded fast, the WHO realized it could not keep natural remedies outside the system any longer. In 2004, it issued landmark guidelines specifically for monitoring herbal medicines, and that formally brought them under the international pharmacovigilance framework.[12] That shift matters more than people sometimes admit. Now, when adverse reactions are investigated, health authorities actively look for herb-drug interactions, adulteration, and contamination. That is necessary, not optional, since “natural” does not automatically mean safe. In practice, herbal products are now expected to meet the same demanding safety standards as modern synthetic medicines.

5. PHARMACOVIGILANCE IN INDIA AND THE ROLE OF THE IP

5.1 The Unique Landscape of Indian Healthcare

India has one of the most complicated healthcare systems anywhere. It is not only a huge market for modern synthetic drugs; it also runs a long-standing parallel system built on traditional medicine. Ayurveda, Yoga, Unani, Siddha, and Homeopathy, grouped together as AYUSH, are still used by millions. In practice, many people take allopathic medicines and herbal remedies at the same time, often without much discussion between providers. That makes it difficult to trace adverse reactions across such a wide population. To deal with this, the government introduced the Pharmacovigilance

Programme of India (PvPI), which works as the national watchdog for drug safety.[13]

5.2 The Critical Role of the Indian Pharmacopoeia (IP)

Drug safety cannot be monitored properly if the contents of a medicine are unclear. It is hard enough with standard tablets, and with herbal extracts the problem becomes even messier when different batches contain different levels of active compounds. The Indian Pharmacopoeia (IP) is what keeps that from turning into complete confusion. The IP is the official, legally binding standard book for drugs in India, published by the Indian Pharmacopoeia Commission (IPC). The IPC also serves as the National Coordination Centre for the PvPI network.[14] Inside the IP are detailed monographs, which are really strict scientific specifications that define purity, strength, and quality before a drug can be sold. When a doctor reports a serious adverse reaction, investigators use these standards to judge whether the drug itself is at fault or whether the problem came from a contaminated or substandard batch. That distinction matters a lot.

5.3 Standardizing Herbal Medicine and Opium

For a long time, the IP was mostly cantered on synthetic drugs. That changed as herbal pharmacovigilance became more important, and the IP began including monographs for botanical medicines. This was a major shift for plant-based safety in India.[15] The issue is even more sensitive with *Papaver somniferum*. India is among the few countries allowed by the United Nations to cultivate raw opium for medicinal and scientific purposes. The gap between a useful dose of morphine and a dangerous overdose is very narrow, so the Indian Pharmacopoeia sets strict rules for processing, extraction, and measurement. Every legal batch has to match the chemical profile given in the IP. That gives health authorities a real way to track safety and spot illicit or adulterated products before they spread further.[16]

5.4 Bridging the Gap in AYUSH

Even with PvPI and the IP in place, herbal safety monitoring in India is still uneven. The AYUSH Suraksha network was created to record adverse events linked to traditional medicines, which is a necessary step. Yet underreporting remains a serious weakness. Many practitioners are not fully trained in these systems, and patients often leave out herbal use when they speak to allopathic doctors. That silence creates gaps. Strengthening the link between the IP's standard-setting laboratories and ordinary clinics is not just helpful, it is necessary if consumers are to be protected properly.[17]

6. THE CORE FUNCTIONS OF PHARMACOVIGILANCE

6.1 More Than Just Data Collection

It is easy to think of pharmacovigilance as a giant filing cabinet where doctors drop complaints about side effects. That picture is neat, but it is wrong. Pharmacovigilance is active, constantly moving, and honestly far more demanding than simple record keeping. According to the World Health Organization, the discipline rests on four core pillars: detection, assessment, understanding, and prevention of adverse effects.[18] The purose is not just to note that what problem it caused, but it is to figure out why it happened and stop it from happening again.

6.2 Detection: Catching the "Signal"

The first job is detection. In pharmacovigilance, one report of a side effect is usually just background noise. Once several reports of a similar adverse event start coming in from different patients, that noise becomes a "safety signal".[19] This is where herbal medicine becomes difficult. With a standardized opiate derived from *Papaver somniferum*, doctors know the classic warning signs, such as pinpoint pupils or slowed breathing. Herbal extracts are messier. The signs can be vague, and patients may only mention nausea, fatigue, or a general sense that something feels off. Detection depends heavily on "spontaneous reporting," which means the whole system leans on healthcare professionals and patients to speak up when they notice a problem. That sounds simple. In practice, it is not.

6.3 Assessment: Proving Causality

Once a signal appears, the harder work starts: assessment. A patient may take an herbal supplement and later develop liver damage, but that does not automatically mean the supplement caused it. There could be another illness involved, or the patient may already be using other toxic drugs. To get closer to the truth, pharmacovigilance experts use "causality assessment." They look closely at timing: did the symptoms begin after the medicine was taken? Did they improve when the medicine was stopped, or de-challenge? Did they return when it was taken again, or re-challenge? Standard tools such as the WHO-UMC causality scale help classify the link from "doubtful" to "certain".[20] Herbal medicines make this even more complicated. Patients often combine botanicals with synthetic drugs, so investigators have to untangle a dense mix of possible herb-drug interactions before they can point to the real cause.

6.4 Prevention: Taking Action to Protect Patients

The final goal of all this detection and assessment is prevention. If pharmacovigilance stops at understanding the risk, then it has not done its job. Once an adverse drug reaction is confirmed, regulatory bodies have to act and reduce that risk.[21] The response really depends on how serious the problem is. If an herbal product gets contaminated with heavy metals or mixed with synthetic drugs, the whole batch should be recalled from the

market. If the issue is dosage, for example when patients take too much raw *Papaver somniferum* extract and end up with respiratory depression, the better response might be revised clinical guidelines, a public warning, or stricter labels with lower dose limits. These steps matter because they protect the basic balance: medicine is supposed to help more than harm. Pharmacovigilance is what stops that balance from quietly slipping.

7. EXPANDED HISTORY OF HERBAL MEDICINE

For most of human history, people tended to assume that anything coming from a plant was basically safe. If it grew from the ground, many believed it could not really harm the person using it. Because of that mindset, scientific attention was rarely aimed at the less obvious dangers, especially the effects that might appear after long-term use or when herbs were taken alongside other medicines. Most written records from those periods were simply references, almost like lists, of plants believed to treat certain problems. There was very little interest in side effects, and honestly almost no serious record of what might happen if someone kept using the same plant for years or mixed it with another treatment.

Later, when synthetic drugs became more common, the attitude started to shift. Physicians, and also government regulators, began to look much more carefully at whether herbs were actually safe and how they could interact with medications already being used by patients. That change mattered a lot. Even then, herbs still sat outside most formal health safety systems, which seems like a pretty major gap when so many people were clearly still using them.

In recent years, health authorities and both local and national governments have taken herbal products more seriously. They are no longer treated as some minor side topic. In many countries, new laws now require these products to be registered, monitored, and tested for safety using proper data. Even with that progress, the way this information is collected and used is still developing, and it should keep developing. The point is not to reject herbs outright. It is to make sure their benefits are real, their risks are understood, and people are not harmed simply because a product was assumed to be harmless from the start.

7.1 Early History: A Focus on Healing Over Hazards

Early medical history was mostly about healing, not about hazards. In ancient and medieval periods, plants sat at the center of medical practice, and that focus shaped how people wrote about them. You can see it in famous herbals from ancient Egypt, especially the Ebers Papyrus, in Greek works like Dioscorides' *De Materia Medica*, and later in European manuscripts such as the Anglo-Saxon Herbarium and the Red Book of Hergest. These texts were mainly records of useful plants and their therapeutic value. They were not really concerned with toxicity or adverse reactions, which feels striking now.

- That silence did not mean toxic plants were harmless. It came from deeper problems in how medicine worked at the time. First, disease was usually explained through spiritual ideas or humoral theory, not through anything close to physiology or molecular science. As a result, attention stayed on balancing the body rather than identifying poisonous effects.
- Then there was the issue of documentation. People did not have reliable ways to observe, record, or compare harmful reactions after taking medicinals. That gap matters a lot. If patterns cannot be tracked, they are easy to miss or simply ignore.
- On top of that, blame often landed in the wrong place. Negative effects were usually pinned on the patient's nature, fate, or poor administration, not on the plant itself. That made it easy for herbalists like Gerard, Parkinson, and Culpepper to keep pushing the idea that botanical medicine was safe and beneficial.

7.2 Early Pharmacopoeias: Minimal Safety Oversight

Early pharmacopoeias, including the *Pharmacopoeia Londinensis*, were meant to standardize medical formulas, and that mattered. Yet they gave very little attention to safety. Mentions of possible harm from drugs were usually brief, indirect, and easy to miss. In practice, that meant people had almost no real guidance about adverse effects. Even worse, there was no proper system for gathering information on injuries caused by medicines, which feels like a major weakness when looking back at that period.

7.3 The Turning Point: The Rise of Synthetic Chemistry

A real shift came with the rise of synthetic chemistry. Once inorganic and organic synthetic medicines began spreading in the 1900s, and kept developing after that, drug production changed fast. These medicines could be made more quickly and often came out far more potent than earlier versions. That was impressive, honestly, though it also carried an obvious cost. Stronger products reached more people, and more people were harmed by these "new" medicines. That pressure made a different kind of pharmacovigilance necessary, one focused on actually watching medicine safety in a systematic way rather than assuming problems would stay limited. As these newer safety systems developed, herbal medicines were pushed aside. They were often treated as outdated, or simply assumed to be low-risk. I think that assumption was too convenient. Because of it, herbal remedies were mostly left out when safety data was collected and when the newer monitoring systems were being built. That neglect shaped the whole field in a narrow way.

7.4 Modern Era: The Gradual Acknowledgment of Herbal Risk

Herbal "natural" products were being sold widely in retail stores. Even so, with huge numbers of herbal and other natural products available across the country,

reports of serious liver toxicity started to rise, along with deadly herb-drug interactions, for example St. John's Wort with anti-viral medications, and cases of herbs contaminated with harmful materials. That was alarming, honestly, and it pushed lawmakers toward new rules and regulations.[22] The European Directive on Traditional Herbal Medicinal Products of 2004 became a major step in regulating herbal medicines whereby.

- All herbal products have to be formally registered. They can only be advertised for treating minor ailments, which is a fair limit, honestly.
- Also, each product must show a traditional history of use, at least 30 years, with evidence that people have used it safely.
- Reporting any suspected adverse events, and assessing them properly, is the manufacturer's responsibility. In the United Kingdom, registered herbal medicines now have to meet almost the same market surveillance and control standards as synthetic medicines, and that seems like a necessary step.

7.5 Current Challenges and Future Directions

Current challenges are still pretty serious, even though monitoring activities have increased over time. There still is not enough data, and the available indices are too limited to compare herbal and traditional medicine properly for safety. A lot of herbal products are not represented accurately, mainly because many consumers self-medicate and never speak to a healthcare professional. At the same time, plenty of these products enter the market without enough clinical research, which is honestly frustrating considering how widely they are used. Effective pharmacovigilance is clearly necessary if we want to judge whether the therapeutic benefits of herbal medicines really outweigh the risks. This depends on giving both healthcare professionals and consumers complete, direct information about possible safety hazards as well as the real healing benefits linked to herbal medication use.

Table 1: Herbal pharmacovigilance history.

Period / era	Key millstone	Focus and impact
Ancient Era	Empirical observation	Early texts documented healing and toxic effects. Safety was based on traditional use.
1960s	The Thalidomide Catalyst	While not herbal, this tragedy birthed modern Pharmacovigilance (PV).
1999s	The Aristolochic Incident	Turning point; Dietary supplements containing Aristolochic caused kidney failure.
2000s	The Ephedra Ban	FDA banned Ephedra due to cardiovascular risks.
2004	WHO Guidelines	WHO published first specific Guidelines on Safety Monitoring of Herbal Medicines.
Modern Day	Vigilance 2.0	Focus on Herb-Drug Interactions (HDI) and molecular fingerprinting.

8. THE CRITICAL IMPORTANCE OF HERBAL PHARMACOVIGILANCE

A lot of people still believe that if something comes from nature, it must be mild or harmless. That belief is comforting, honestly, though it is also wrong. Nature can heal, yes, but it can also harm. It is full of powerful chemicals, and some of them are dangerous. Herbal medicine, in particular, is not simple at all. A synthetic drug usually contains one purified active compound. A plant extract does not work that way. It is a messy mix of dozens, sometimes even hundreds, of chemical substances. In practice, taking an herbal remedy can feel a lot like taking a small drug combination. The bigger problem is consistency. The place where the plant grows, the soil, even the climate can change the strength of those compounds quite a lot. Pharmacovigilance is what helps detect adverse reactions, improve standardization, and protect consumers from risks that often stay hidden.[23]

9. ADVERSE DRUG REACTIONS (ADRs) OF HERBAL MEDICINES

Table 2: Common ADRs Linked to Herbal Medicines.

SYSTEM	COMMON REACTIONS
Gastrointestinal	Nausea, Vomiting, Diarrhea , Abdominal pain, Loss of appetite.
Hepatic (Liver)	Hepatotoxicity (liver injury), Jaundice, Elevated liver enzymes, Fatigue.
Cardiovascular	Hypertension (high blood pressure), Palpitations, Arrhythmia, Tachycardia.
Central Nervous System	Dizziness, Insomnia, Headache, Tremors, Agitation or anxiety.
Dermatological	Photosensitivity, Contact dermatitis, Urticaria (hives), Rash.
Renal (Kidney)	Nephrotoxicity, Crystalluria, Changes in urinary frequency.

9.1 Possible Clinical Risks of Botanicals

- **The Problem of Unpredictable Toxicity:** Unlike synthetic drugs where side effects are usually well-mapped, herbal ADRs are often "idiosyncratic." This means they can happen suddenly and unpredictably because of the complex chemical mix inside a single plant. A person might use a herbal tea for years without an issue, only to develop sudden liver

inflammation or a severe skin rash because a new batch had a slightly different chemical profile or was grown in different soil.[24]

- **The "Natural" Allergic Response:** Because plants contain various proteins and pollens, allergic reactions are a major clinical risk. These can range from mild itching to severe anaphylaxis. What makes this difficult for clinicians is that patients often don't realize their "natural" supplement is the cause, leading to a delay in recognizing the allergic "triad" of swelling, respiratory distress, and rapid heart rate. Recognizing these signs early is crucial for stopping the botanical use before it becomes life-threatening.
- **Chronic Organ Stress and Cumulative Damage:** Many people believe that since herbs are mild, they can be taken indefinitely. This is a mistake. Over time, certain alkaloids and heavy metal contaminants often found in unregulated herbs can build up in the body. This leads to chronic stress on the kidneys and liver. Even if the brain "feels" fine, the organs may be struggling to process the constant load of foreign plant compounds, eventually leading to permanent organ damage or failure if the usage isn't monitored by a professional.[25]

10. HERB-DRUG INTERACTIONS

10.1 The Danger of Multi-Drug Cocktails

When judging the safety of herbal medicine, looking at the plant by itself is not enough. In real healthcare, people often mix botanical remedies with prescription drugs and even common over-the-counter medicine. That is where the real danger starts. When a strong herb like *Papaver somniferum* gets into the body, it does not work alone. It changes the body's whole physiological setting. This falls under Herb-Drug Interactions (HDIs), and honestly, it is one of the most serious concerns in modern pharmacovigilance.[26] Opium mainly works as a Central Nervous System (CNS) depressant. Its active alkaloids, especially morphine and codeine, are processed by liver enzymes, mainly through the Cytochrome P450 (CYP450) pathway. If another drug depends on those exact enzymes too, the body can end up with a serious metabolic traffic jam. That is not a minor issue. It can turn a manageable dose into something much more dangerous.

10.2 Synergistic Toxicity (The Multiplier Effect)

The riskiest interactions with opium usually are not about one substance canceling another out. The real problem is synergy. In simple terms, when an opiate is taken with another drug that also slows the brain or breathing, the result is not just stronger. It can become dramatically worse. For instance, a patient using a moderate and traditionally safe dose of medicinal opium could still suffer a fatal overdose after drinking alcohol or taking a regular anti-anxiety drug on the same day. The combined depressant action can overwhelm the brainstem and cause breathing to stop.[27]

Table 3: Severe Herb-Drug Interactions of Opium.

Interacting Drug Class	Common Examples	Mechanism	Clinical Outcome
Alcohol	Beer, Wine	Additive CNS depression	Severe/Fatal. Resp. depression
Benzodiazepines	Diazepam	GABA receptor synergy	Fatal Risk. Deep coma
MAO Inhibitors	Phenelzine	Neurological overload	Severe. Serotonin Syndrome
Anticholinergics	Atropine	Slower digestive motility	Extreme constipation
CYP3A4 Inhibitors	Erythromycin	Blocks clearing enzyme	Severe. Toxic buildup

10.3 The Role of Pharmacovigilance in Preventing HDIs

The long list of serious interactions above shows why the idea that "natural is safe" is not just wrong, it is dangerous. A patient may use a synthetic drug for years without any issue, then suddenly face a major medical emergency after trying a "natural" poppy extract for a chronic cough or stubborn joint pain.[28] This is exactly where pharmacovigilance matters. By following patient reports and using large databases such as VigiBase, health authorities can spot these risky combinations in real clinical settings. Once those patterns are clear, regulators can issue "Black Box Warnings" on prescription drugs, which pushes doctors and pharmacists to directly warn patients not to mix their medicines with certain botanical products.

11. CHALLENGES IN HERBAL PHARMACOVIGILANCE

11.1 The Crisis of Underreporting

Pharmacovigilance depends on one basic act: someone has to report the adverse reaction. If a doctor or patient never files that report, the system quietly assumes the drug is harmless. With herbal medicines, that assumption is dangerously misleading. Underreporting is not a small flaw here; it is a widespread problem. Only a tiny share of adverse herbal reactions ever reach global safety databases.[29] Reasons for this include the "Natural" Blind Spot, the Communication Gap, and Clinician Limitations.[30]

11.2 The Regulatory Loophole

The second major problem in herbal pharmacovigilance is the weak and inconsistent regulation across countries. A synthetic drug has to survive years of strict pre-market testing before it reaches patients. Herbal medicines often avoid that level of scrutiny.[31] In many places, including

the United States, herbal products are treated as "dietary supplements" or "foods" rather than medicines. Weak oversight also means weak quality control. Manufacturers are often left to police themselves, and the results can be ugly. Global pharmacovigilance centers regularly find "natural" products contaminated with heavy metals, pesticides, or even secretly mixed with synthetic prescription drugs to make them look more effective.[32] Until health authorities enforce unified Good Manufacturing Practices (GMP), pharmacovigilance will keep struggling uphill.

12. REGULATORY ASPECTS OF HERBAL MEDICINES

12.1 The Global Regulatory Divide

Herbal medicines sit in an awkward space between "food" and "pharmaceuticals." A botanical extract that needs a doctor's prescription in Germany can be sold casually beside chewing gum at a gas station in the United States. Even now, two systems shape most of the world's thinking on herbal safety: the European Union's strict directives and the FDA's guidelines in the United States.

12.2 The European Approach: The 2004 Directive (THMPD)

The EU introduced the Traditional Herbal Medicinal Products Directive (Directive 2004/24/EC), which changed herbal regulation across member states in a major way. The directive accepted a reality: forcing old herbal remedies to go through the same expensive clinical trials as brand-new synthetic drugs was not practical. Key points include Proof of Tradition, Restricted Claims, and Mandatory Pharmacovigilance.[33]

12.3 The United States Approach: FDA Guidelines and DSHEA

The United States takes a much looser, market-based route. Under the Food and Drug Administration (FDA), most herbal remedies fall under the Dietary Supplement Health and Education Act (DSHEA) of 1994 instead. Key features include No Pre-Market Approval, Current Good Manufacturing Practices (cGMP) [34], and Post-Market Surveillance through MedWatch.[35]

12.4 The Need for Global Harmonization

Organizations such as the WHO are pushing hard for regulatory harmonization. Until countries agree on a common baseline for how plants are registered, tracked, and tested, safety systems will stay broken into separate pieces.[36]

13. CAUSALITY ASSESSMENT AND THE WHO-UMC SCALE

13.1 Separating Coincidence from Causation

Picture a patient who takes a traditional herbal opium extract for joint pain and, two days later, starts having severe nausea and trouble breathing. Did the extract trigger the reaction, or was the patient already heading toward illness for some unrelated reason? Investigators have to judge whether the drug actually caused the harm. That judgment is called causality assessment.

13.2 The WHO-UMC Causality Assessment Scale

The World Health Organization and the Uppsala Monitoring Centre (UMC) created a practical system: the WHO-UMC Causality Assessment Scale. Investigators examine timing sequence, competing causes, dechallenge, and rechallenge. After those questions are answered, investigators place the ADR into a standardized category.[37]: Certain, Probable / Likely, Possible, or Unlikely.

13.3 The Herbal Complication

Using the WHO-UMC scale for a complex botanical like *Papaver somniferum* is a far harder story. Potency variation in raw herbs makes the rechallenge part of the WHO-UMC scale especially tricky in herbal pharmacovigilance.[38]

14. RECENT ADVANCES IN HERBAL PHARMACOVIGILANCE

14.1 The Shift to "Vigilance 2.0"

The scientific community is moving toward Vigilance 2.0. This means moving from passive reporting to active surveillance.[39] Herbal medicine has always been messy, and this proactive model finally gives researchers stronger tools to control that chaos.

14.2 Key Technological Innovations

- **Molecular Fingerprinting and DNA Barcoding:** Scientists use HPLC and mass spectrometry to build chemical "fingerprints" to catch missing alkaloids or foreign chemicals. DNA barcoding confirms the exact species inside a supplement.[40]
- **AI-Driven Signal Identification:** AI systems scan enormous global databases like VigiBase to pick up hidden statistical links.[41]
- **Social Listening:** Regulatory agencies use Natural Language Processing (NLP) to scan social media platforms as early warning signs.[42]
- **Precision Medicine:** Advances in pharmacogenomics help doctors spot genetic profiles, such as a CYP2D6 mutation, that may increase toxicity risks.[43]

15. LIMITATIONS AND FUTURE SCOPE

15.1 Current Limitations

Inherent chemical variability, data fragmentation, infrastructure gaps in LMICs, and the complexity of HDIs remain stubborn problems.

15.2 Future Scope and Emerging Paradigms

The next decade will be shaped by Real-World Evidence (RWE) integration, unified global databases, and predictive toxicology via "omics" technologies. Bridging the clinician-patient divide through education will also be critical.

16. CONCLUSION

Global reliance on herbal medicines is not some leftover from the past; it's now a growing part of modern healthcare. Yet the history of *Papaver somniferum* shows that botanical treatments can be powerful and chemically messy. The stubborn idea that "natural automatically equals safe" is one of the biggest blind spots in public health today. Tracking these effects is difficult due to underreporting and regulatory gray areas. Fortunately, herbal pharmacovigilance is finally shifting toward "Vigilance 2.0," shaped by AI and real-world data. In the end, modern herbal pharmacovigilance should not block access to traditional healing; it should protect and strengthen it through serious scientific oversight.

17. REFERENCES

1. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol*, 2014; 4: 177.
2. ResearchGate Review. Safety, Toxicity, and Adverse Effects of Herbal Medicines: A Critical Review. *ResearchGate*.
3. Stephens MDB. The Dawn of Drug Safety, 2nd ed. Hampshire: *George Mann Publications*; 2012.
4. Nikita R. Nikam, Rohan R. Vakhariya, Dr. C. S. Magdum. Pharmacovigilance: An Overview. Asian J. Res. Pharm. Sci, 2019; 9(2): 107-111. doi: 10.5958/2231-5659.2019.00016.X
5. Sartori D, Aronson JK, Brand JS, Gauffin O, Hedfors Vidlin S, Norén GN, Onakpoya IJ. Signals of Adverse Reactions to Herbal Medicines: Evidence and Document Analysis Based on a Scoping Review. Drug Saf, 2025 Dec; 48(12): 1339-1352. doi: 10.1007/s40264-025-01580-3. Epub 2025 Jul 2. PMID: 40601107; PMCID: PMC12605554.
6. Rohilla A, et al. Pharmacovigilance: needs and objectives. *J Adv Pharm Edu Res*, 2012; 2(4): 201-5.
7. Alhat BR. Pharmacovigilance: an overview. *Int J Res Pharm Chem*, 2011; 1(4): 2231-781.
8. Routledge P. 150 years of pharmacovigilance. *The Lancet*. 1998; 351(9110): 1200-1.
9. WHO. WHO Programme for International Drug Monitoring: 50 years of safety. *World Health Organization*; 2018.
10. S. S. Shuka, Bina Gidwani, R. Pandey, S. P. Rao, V. Singh, Amber Vyas. Importance of Pharmacovigilance in Indian Pharmaceutical Industry. Asian J. Res. Pharm. Sci, Jan.-Mar, 2012; 2(1): 04-08.
11. WHO. Guidelines on Safety Monitoring of Herbal Medicines. Geneva: *World Health Organization*; 2004.
12. Kalaiselvan, Vivekanandan; Thota, Prasad; Singh, Gyanendra Nath1. Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian Journal of Pharmacology, Nov–Dec 2016; 48(6): 624-628. | DOI: 10.4103/0253-7613.194855.
13. IPC. Indian Pharmacopoeia 2022: History and Monographs. Ghaziabad: *Indian Pharmacopoeia Commission*; 2022.
14. Soundalgekar S, et al. HPTLC fingerprinting and anti-asthmatic activity of roots. *Indian J Nat Prod*, 2021; 35(1).
15. Chauhan VS. Standardizing herbs and intermediates-newer approaches. *The Pharma Review*, 2006; 2: 37-44.
16. Rahman SZ, Khan RA, Latif A. Importance of pharmacovigilance in Unani system of medicine. Indian J Pharmacol, 2008 Feb; 40(Suppl 1): S17-20. PMID: 21369407; PMCID: PMC3038517.
17. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Saf. 1999 Dec; 21(6): 429-47. doi: 10.2165/00002018-199921060-00001. PMID: 10612268.
18. Rawlins MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol. 1988 Jul; 26(1): 1-5. doi: 10.1111/j.1365-2125.1988.tb03356.x. PMID: 3203052; PMCID: PMC1386492.
19. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998 Jul; 19(1): 1-10. doi: 10.2165/00002018-199819010-00001. PMID: 9673854.
20. Jacob D, Marrón B, Ehrlich J, Rutherford PA. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. Drug Healthc Patient Saf, 2013 Apr 15; 5: 105-12. doi: 10.2147/DHPS.S43104. PMID: 23637559; PMCID: PMC3636760.
21. EMA. Traditional herbal medicinal products: Directive 2004/24/EC. *European Medicines Agency*; 2004.
22. Bigoniya P. Pharmacovigilance of herbal medicines: current status. *The Pharma Review*, 2009; 5: 77-88.
23. Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol, 2015 Apr 23; 6: 72. doi: 10.3389/fphar.2015.00072. PMID: 25954198; PMCID: PMC4407580.
24. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci, 2002 Mar; 23(3): 136-9. doi: 10.1016/S0165-6147(00)01972-6. PMID: 11879681.
25. ClinPGx. Codeine and Morphine Metabolic Pathways: The Role of CYP2D6 and CYP3A4. *ClinPGx Database*; 2026.
26. Wikipedia contributors. Opioid overdose: Synergy with Benzodiazepines. *Wikipedia*; 2026.
27. Lasser KE, et al. Timing of new black box warnings and withdrawals for prescription medications. *JAMA*, 2002; 287(17): 2215-2220.
28. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol, 2014 Jan 10; 4:

177. doi: 10.3389/fphar.2013.00177. PMID: 24454289; PMCID: PMC3887317.
29. Akash Jakkannavar, Sneha Patil, Mrityunjaya Patil, Shailendra Suryawanshi. Pharmacovigilance for Herbal Medicines. Asian Journal of Research in Pharmaceutical Sciences, 2024; 14(4): 407-7. doi: 10.52711/2231-5659.2024.00064
30. Swathi. J, D. Nagasamy Venkatesh. A Review of Herbal Regulations in India and Worldwide. Research Journal of Pharmacy and Technology, 2022; 15(3): 1348-2. doi: 10.52711/0974-360X.2022.00225
31. Dal Molim G, et al. Microbial quality of herbal plants. *Curr Pharm Des*, 2016; 22(27): 4264-87.
32. Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol, 2012 Apr 10; 140(3): 513-8. doi: 10.1016/j.jep.2012.01.051. Epub 2012 Feb 9. PMID: 22342381
33. FDA. Current Good Manufacturing Practices (CGMPs) for Dietary Supplements. *FDA.gov*; 2023.
34. FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. *FDA.gov*; 2023.
35. WHO. Safety Monitoring of Medicinal Products. Geneva: *World Health Organization*; 2002.
36. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol, 2008 Aug; 64(8): 743-52. doi: 10.1007/s00228-008-0475-9. Epub 2008 Jun 4. PMID: 18523760.
37. Skalli S, et al. Causality assessment of adverse reactions to herbal medicines. *Evid-Based Valid Herbal Med*, 2022; 1: 239-50.
38. Vikas P. Londhe, Rahul Chanshetti, S.N. Dhole. Pharmacovigilance: Past, Present and Future. Asian Journal of Pharmaceutical Research, 2024; 14(2): 175-2. doi: 10.52711/2231-5691.2024.00029
39. Chen S, Yin X, Han J, Sun W, Yao H, Song J, Li X. DNA barcoding in herbal medicine: Retrospective and prospective. J Pharm Anal, 2023 May; 13(5): 431-441. doi: 10.1016/j.jpha.2023.03.008. Epub 2023 Apr 5. PMID: 37305789; PMCID: PMC10257146.
40. Bate A, Hobbiger H. AI and pharmaceutical pharmacovigilance. *Drug Saf*, 2021; 44: 11-15.
41. Sarker A, O'Connor K, Ginn R, Scotch M, Smith K, Malone D, Gonzalez G. Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter. Drug Saf, 2016 Mar; 39(3): 231-40. doi: 10.1007/s40264-015-0379-4. PMID: 26748505; PMCID: PMC4749656.
42. Pirmohamed M. Pharmacogenomics and ADRs. *Br J Clin Pharmacol*, 2014; 77(4): 598-600.